Elevance Health, Inc. $ELV Position Increased by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC grew its position in Elevance Health, Inc. (NYSE:ELV) by 58.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 52,295 shares of the company’s stock after purchasing an additional 19,339 shares during the period. Exchange Traded Concepts LLC’s holdings in Elevance Health were worth $18,332,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in ELV. American Century Companies Inc. grew its position in Elevance Health by 12.0% during the 2nd quarter. American Century Companies Inc. now owns 97,930 shares of the company’s stock worth $38,091,000 after purchasing an additional 10,486 shares in the last quarter. CreativeOne Wealth LLC lifted its holdings in shares of Elevance Health by 13.2% in the second quarter. CreativeOne Wealth LLC now owns 1,503 shares of the company’s stock valued at $585,000 after purchasing an additional 175 shares in the last quarter. J.W. Cole Advisors Inc. lifted its holdings in shares of Elevance Health by 36.4% in the second quarter. J.W. Cole Advisors Inc. now owns 2,457 shares of the company’s stock valued at $956,000 after purchasing an additional 656 shares in the last quarter. Inceptionr LLC acquired a new stake in shares of Elevance Health in the second quarter worth $465,000. Finally, Choreo LLC boosted its position in shares of Elevance Health by 14.3% in the second quarter. Choreo LLC now owns 4,863 shares of the company’s stock worth $1,892,000 after buying an additional 610 shares during the period. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Price Performance

ELV opened at $286.23 on Friday. The stock has a market cap of $63.17 billion, a price-to-earnings ratio of 11.39, a PEG ratio of 1.57 and a beta of 0.51. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $458.75. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The stock has a fifty day moving average price of $322.20 and a 200 day moving average price of $332.71.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. During the same quarter in the previous year, the company posted $3.84 earnings per share. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th were paid a $1.72 dividend. This represents a $6.88 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend was Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio (DPR) is presently 27.39%.

Analyst Ratings Changes

ELV has been the topic of several recent analyst reports. Wolfe Research set a $425.00 price target on Elevance Health and gave the company an “outperform” rating in a research report on Thursday, January 8th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $332.00 price objective on shares of Elevance Health in a research report on Thursday, January 29th. Guggenheim dropped their target price on Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a report on Thursday, January 29th. UBS Group set a $400.00 price target on shares of Elevance Health in a research report on Thursday, January 29th. Finally, Wells Fargo & Company decreased their price target on shares of Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a report on Friday, January 30th. Twelve research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $387.40.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.